You had a very good point there. It was in Hikma press release that they cited the 1 bil sales. They had clear intention to infringe in the whole V franchise. FDA SHOULD STOP THEM.
JDUR, I found this post and one of your early posts to be interesting because you bring up 5% of usage, less than 22 weeks and dr budoff (amrn witness, right?), and nobody’s gave it much attention. I wanted to reply but didn’t because as I understand amrn actually won infringement, so should we still worry about this unless generics file cross appeal.
Moreover, like I stated before, amarin should just agree to share high % of royalties with the generics for all non R-IT scripts. Even if they have to split 50% of revenues on 5-10% of sales, that would be a huge win. And i don’t think it will be 5-10% of total sales
News 
Market Data 
Discover 
